Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastric Cancer”

189 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 189 results

Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc. 500
Post-approval studies (Phase 4)Not Yet RecruitingNCT07829757
What this trial is testing

Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)UnknownNCT05141747
What this trial is testing

MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Gastric CancerMetastatic HER2 Positive Gastroesophageal Junction Cancer
Shanghai Miracogen Inc. 60
Testing effectiveness (Phase 2)Ended earlyNCT00447226
What this trial is testing

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Who this might be right for
Cancer
GlaxoSmithKline 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07126561
What this trial is testing

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Who this might be right for
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
University of Chicago 43
Very early researchUnknownNCT05411432
What this trial is testing

Clinical Study of 68Ga Labeled HER2 Affibody Analogues

Who this might be right for
HER2-positive Breast Cancer and Gastric Cancer
Xijing Hospital 56
Testing effectiveness (Phase 2)Study completedNCT02015169
What this trial is testing

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Who this might be right for
HER2-positive Gastric Cancer Patients With Liver Metastasis
Samsung Medical Center 32
Large-scale testing (Phase 3)Active Not RecruitingNCT03504397
What this trial is testing

Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Study completedNCT04499924
What this trial is testing

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
Seagen Inc. 17
Early research (Phase 1)Ended earlyNCT03680560
What this trial is testing

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Who this might be right for
Solid TumorHER-2 Protein Overexpression
Cogent Biosciences, Inc. 6
Testing effectiveness (Phase 2)UnknownNCT05111444
What this trial is testing

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Fudan University 65
Testing effectiveness (Phase 2)Looking for participantsNCT05975749
What this trial is testing

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

Who this might be right for
Gastric Cancer
Fudan University 114
Testing effectiveness (Phase 2)UnknownNCT04819971
What this trial is testing

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Who this might be right for
Stomach Cancer
The First Affiliated Hospital of Zhengzhou University 67
Early research (Phase 1)Active Not RecruitingNCT04511871
What this trial is testing

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Who this might be right for
Solid TumorGastric CancerBreast Cancer+2 more
Shanghai PerHum Therapeutics Co., Ltd. 12
Testing effectiveness (Phase 2)Looking for participantsNCT05965479
What this trial is testing

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Who this might be right for
Gastrooesophageal Cancer
University of Southampton 25
Not applicableLooking for participantsNCT06846996
What this trial is testing

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT04492488
What this trial is testing

MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Who this might be right for
Advanced Solid TumorsAdvanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction Cancer
Shanghai Miracogen Inc. 129
Testing effectiveness (Phase 2)WithdrawnNCT02713984
What this trial is testing

A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer

Who this might be right for
Breast CancerOvarian CancerLung Cancer+4 more
Zhi Yang
Early research (Phase 1)Temporarily pausedNCT04650451
What this trial is testing

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Who this might be right for
HER-2 Gene AmplificationHER2-positive Gastric CancerHER2-positive Breast Cancer+2 more
Bellicum Pharmaceuticals 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 29
Next Page
50
565